Halyard Health (HYH) Given News Sentiment Score of 0.12

News stories about Halyard Health (NYSE:HYH) have been trending somewhat positive on Tuesday, Accern reports. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Halyard Health earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 45.9933842909389 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Halyard Health (HYH) traded down $0.71 during trading hours on Tuesday, reaching $47.41. The company’s stock had a trading volume of 418,808 shares, compared to its average volume of 347,246. The company has a quick ratio of 1.19, a current ratio of 2.13 and a debt-to-equity ratio of 0.49. Halyard Health has a one year low of $35.24 and a one year high of $50.99. The firm has a market capitalization of $2,267.35, a PE ratio of 23.16, a price-to-earnings-growth ratio of 2.62 and a beta of 1.77.

Halyard Health (NYSE:HYH) last released its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.13. Halyard Health had a return on equity of 8.65% and a net margin of 3.52%. The company had revenue of $401.40 million for the quarter, compared to analysts’ expectations of $394.54 million. During the same period in the prior year, the firm earned $0.48 earnings per share. The firm’s revenue was up 1.0% compared to the same quarter last year. equities analysts predict that Halyard Health will post 2.08 earnings per share for the current fiscal year.

A number of research analysts have commented on HYH shares. Zacks Investment Research upgraded Halyard Health from a “sell” rating to a “hold” rating in a research note on Thursday, October 19th. ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a research note on Saturday, November 4th. BidaskClub upgraded Halyard Health from a “hold” rating to a “buy” rating in a research note on Saturday, August 19th. TheStreet cut Halyard Health from a “b-” rating to a “c+” rating in a research note on Monday, October 30th. Finally, Stifel Nicolaus restated a “buy” rating and set a $45.00 price target on shares of Halyard Health in a research note on Thursday, September 21st. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $44.00.

TRADEMARK VIOLATION NOTICE: “Halyard Health (HYH) Given News Sentiment Score of 0.12” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/05/halyard-health-hyh-given-news-sentiment-score-of-0-12.html.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Insider Buying and Selling by Quarter for Halyard Health (NYSE:HYH)

What are top analysts saying about Halyard Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Halyard Health Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit